

June 2025 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

New Drug Review			
Drug	Indication	Formulary Coverage	Effective Date
Alyfrek (vanzacaftor, tezacaftor, and deutivacaftor)	Treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Formulary	8/1/2025
Itovebi (inavolisib) Protected Class Drug	PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (mBC) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for the treatment of adults with endocrine-resistant, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.	Formulary	8/1/2025
Sofdra (sofprionium)	Hyperhidrosis of axilla	Non-Formulary	N/A
Cobenfy (xanomeline/trospium)	Treatment of schizophrenia in adults	Formulary	8/1/2025
Tryvio (aprocitentan)	Treatment of hypertension (HTN) in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other drugs.	Non-Formulary	N/A

June 2025 Pharmacy & Therapeutics Committee Decisions

Aqneurisa (levacetylleucine)	Aqneurisa is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥ 15 kg.	Non-Formulary	N/A
Miplyffa (arimoclomol)	Miplyffa is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.	Non-Formulary	N/A

New Indications Review		
Drug	Current Formulary Status	Recommendation
Odefsey (emtricitabine-rilpivirine-tenofovir alafenamide) 200-25-25 mg tablets for HIV in adults and pediatric patients weighing ≥ 25 kg indication expansion	Formulary	No change
Sublocade (buprenorphine ER) 100 mg/0.5 mL & 300 mg/1.5 mL SQ syringes for moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of transmucosal buprenorphine or are already being treated with buprenorphine indication expansion	Non-Formulary	No change
Adcetris (brentuximab vedotin) IV vial in combination with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma	Non-Formulary	No change
Tevimbra (tislelizumab) in combination with platinum-containing chemotherapy for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma whose tumors	Non-Formulary	No change

June 2025 Pharmacy & Therapeutics Committee Decisions

express PD-L1 (≥ 1)		
Furoscix (furosemide) 80 mg/10 mL SQ On-body infusor for edema in adults with chronic kidney disease, including nephrotic syndrome	Non-Formulary	No change
Odactra (house dust mite allergen extract) tablets for house dust mite allergies for patients 5 to 65 years age expansion	Non-Formulary	No change
Synjardy [XR] (empagliflozin-metformin [ER]) tablets to reduce the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with type 2 diabetes & CKD at risk of progression	Formulary	No change
Baqsimi (glucagon) 3 mg nasal powder for severe hypoglycemia in patients ≥ 1 year with diabetes age expansion	Non-Formulary	No change
Rivfloza (nedosiran) 160 mg/mL SQ injection to lower urinary oxalate levels in patients ≥ 2 years with primary hyperoxaluria type 1 age expansion	Non-Formulary	No change
Susvimo (ranibizumab) 100 mg/mL intravitreal ocular implant for diabetic macular edema in patients who previously responded to at least 2 intravitreal injections of a VEGF inhibitor	Non-Formulary	No change
Soliris (eculizumab) 10 mg/mL IV vial for generalized myasthenia gravis in patients ≥ 6 years age expansion	Non-Formulary	No change

June 2025 Pharmacy & Therapeutics Committee Decisions

Keytruda (pembrolizumab) 25 mg/mL IV solution traditional approval for HER2+ gastric/GEJ cancer	Non-Formulary	No change
Imfinzi (durvalumab) 50 mg/mL IV solution in combination with gemcitabine and cisplatin followed by durvalumab monotherapy for muscle invasive bladder cancer	Non-Formulary	No change
Fabhalta (iptacopan) 200 mg capsules for complement 3 glomerulopathy to reduce proteinuria	Non-Formulary	No change
Cabometyx (cabozantinib) 20, 40, & 60 mg tablets for neuroendocrine tumors	Formulary	No change
Rinvoq (upadacitinib) 15 mg ER tablets for giant cell arteritis	Formulary	No change
Isturisa (osilodrostat) 1 & 5 mg tablets for endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative	Non-Formulary	No change
Eliquis (apixaban) 2.5 & 5 mg tablets, 0.5 mg tablets for oral suspension, & 0.15 mg sprinkle capsules for oral suspension for VTE in pediatric patients age expansion	Formulary	No change
Sivextro (tedizolid) 200 mg tablets for acute bacterial skin and skin structure infections in pediatric patients age expansion	Non-Formulary	No change
Amvuttra (vutrisiran) 25 mg/0.5 mL prefilled syringe for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis	Non-Formulary	No change

June 2025 Pharmacy & Therapeutics Committee Decisions

Uplizna (inebilizumab) 10 mg/mL IV vials for Immunoglobulin G4-related disease	Non-Formulary	No change
Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for (1) first-line treatment of hepatocellular carcinoma and (2) MSI-H or dMMR colorectal cancer full approval (also applies to nivolumab as single agent)	Non-Formulary	No change

New Generics Review		
Drug	Rationale/Alternative	Recommendation
Galzin (zinc acetate) 25 mg & 50 mg capsules for Wilson's disease authorized generic	An authorized generic launched for zinc acetate capsules.	Non-Formulary
Auranofin 3 mg capsule for rheumatoid arthritis authorized generic	An authorized generic launched for auranofin which is indicated for active classical or definite rheumatoid arthritis in patients who have failed or are intolerant to ≥ 1 nonsteroidal anti-inflammatory drug.	Non-Formulary
Pyzchiva (ustekinumab-ttwe) 45 mg/0.5 mL & 90 mg/mL prefilled syringes for various inflammatory conditions	An additional ustekinumab biosimilar has launched under brand name Pyzchiva in 45 mg and 90 mg formulations.	Non-Formulary
Pyzchiva (ustekinumab-ttwe) 130 mg/26 mL IV vial for IV induction for IBD indications	Additional IV formulation launch of Pyschiva	Non-Formulary
Ivra (melphalan) 90 mg/mL IV vial for multiple myeloma	The 90 mg/mL melphalan IV solution is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.	Non-Formulary
Namzaric (memantine-donepezil) 21-10 mg ER capsule for Alzheimer's disease	A generic for the 21/10 mg strength of Namzaric has launched, joining the 28/10 mg and 14/10 mg strengths	Non-Formulary

June 2025 Pharmacy & Therapeutics Committee Decisions

Otulf (ustekinumab-aaaz) 45 mg/0.5 mL & 90 mg/mL prefilled syringes for various conditions	New Ustekinumab biosimilar for Stelara has launched	Non-Formulary
Purixan (mercaptopurine) 2000 mg/100 mL oral suspension for acute lymphoblastic leukemia	A generic version of Purixan has launched at a marginal price decrease from the branded agent.	Non-Formulary
Xarelto (rivaroxaban) 2.5 mg tablet for anticoagulation	Xarelto (rivaroxaban) 2.5 mg strength recently became generically available, with the higher strength tablets still only available as the brand.	Formulary
Simlandi (adalimumab-ryvk) 80 mg/0.8 mL auto-injector for various inflammatory conditions	New 80mg autoinjector launched	Formulary
Adalimumab-adaz 10 mg/0.1 mL prefilled syringe for various inflammatory conditions	New adalimumab-adaz strength launched	Non-Formulary
Auryxia (ferric citrate) 1 gm (210 mg ferric iron) for hyperphosphatemia and iron deficient anemia in CKD	Ferric citrate authorized generic launched at a ~9% discount from the branded product.	Non-Formulary
Sandostatin LAR Depot (octreotide) 10 mg IM	New generic launch of 10mg alongside 20mg and 30mg	Non-Formulary
Brilinta (ticagrelor) 60 mg & 90 mg tablets antiplatelet therapy	A generic has launched for both the 60 mg and 90 mg strengths of ticagrelor (Brilinta equiv) tablets.	Formulary
Anoro Ellipta (umeclidinium-vilanterol) 62.5-25 mcg/act inhaler for COPD	A new AG of umeclidinium-vilanterol recently launched. Anoro Ellipta is rebated and is lower net cost than the AG, which only has a 5% AWP reduction from the original branded product.	Non-Formulary
Adalimumab-aaty 80 mg/0.8 mL starter kit [3 auto-injectors] for various inflammatory conditions	An 80 mg, 3 dose starter kit for adalimumab-aaty has launched to support new patients using the product for Crohn's, ulcerative colitis, or hidradenitis suppurativa.	Formulary
J&J unbranded Stelara (ustekinumab) products	The manufacturer of Stelara, Johnson & Johnson, has released an unbranded version at a 75% list price discount for the prefilled syringes, 25% discount for the single use SC vial formulation, and 15% discount for the IV vial formulation.	Non-Formulary

June 2025 Pharmacy & Therapeutics Committee Decisions

New or Expanded Formulations		
Drug	Rationale/Alternative	Recommendation
Ergomar (ergotamine) 2 mg sublingual tablet for migraine	An additional ergotamine sublingual tablet NDC launched. This product was originally FDA approved in the 1980s and is not commonly used, with many alternative preferred treatment options for migraine available.	Non-Formulary
Evrysdi (risdiplam) 5 mg tablet for spinal muscular atrophy	Risdiplam for spinal muscular atrophy, previously available only as an oral solution, is now available as a tablet, offering an alternative dosage form for patients able to take tablets.	Non-Formulary
Palforzia (peanut powder) 0.5 mg/1 mg/1.5 mg/3 mg starter pack and 1 mg sprinkle capsules for peanut allergy desensitization	New strengths and packs of peanut powder recently launched to accommodate the dosing regimen for the age expansion down to 1 year of age	Non-Formulary
Rybelsus (semaglutide) 1.5 mg, 4 mg, & 9 mg tablets for type 2 diabetes	Three new strengths of semaglutide launched (previous strengths 3 mg, 7 mg, and 14 mg tablets).	Formulary
Omvo (mirikizumab) 300 mg (100 mg/mL + 200 mg/2 mL) autoinjector and prefilled syringe for Crohn's disease	A new strength and package size presentation of mirikizumab has launched to accommodate the higher dosing required for the recent Crohn's disease indication.	Formulary
Zepbound (tirzepatide) 7.5 mg/0.5 mL & 10 mg/0.5 mL SQ vials for weight management	Higher strength vials of Zepbound have been released, adding 7.5 mg and 10 mg vials to the existing 2.5 and 5 mg vials.	Formulary
Xromi (hydroxyurea) 100 mg/mL oral solution for sickle cell disease	A new liquid formulation of hydroxyurea has launched for patients unable to use solid dosage forms	Non-Formulary
Metaxalone 640 mg tablet for musculoskeletal conditions	Metaxalone 640 mg is a unique strength, joining the generic 400 mg and 800 mg strength tablets. WAC = \$41.75/tab	Non-Formulary
Onapgo (apomorphine) 98 mg/20 mL SQ solution for Parkinson's disease	Onapgo is given by subcutaneous infusion via Onapgo pump. Alternative therapies include injection and inhalation powder	Non-Formulary

June 2025 Pharmacy & Therapeutics Committee Decisions

Zunveyl (benzgalantamine) 5 mg, 10 mg & 15 mg tablets for Alzheimer's disease	Benzgalantamine was designed to reduce the gastrointestinal side effects associated with use of the generically available galantamine	Non-Formulary
Raldesy (trazodone) 10 mg/mL oral solution for major depressive disorder in adults	Raldesy is a new oral solution formulation of trazodone, previously only available in tablet form, indicated for treatment of major depressive disorder in adults.	Formulary
Cortrophin (corticotropin) 40 units/0.5 mL & 80 units/mL SQ prefilled syringes for various indications	Similar to a change for Acthar that occurred last year, Cortrophin is now available as a single-dose prefilled syringe providing 40 or 80 units per injection.	Non-Formulary
Inzirqo (hydrochlorothiazide) 10 mg/mL oral suspension for hypertension & edema associated with heart failure, renal, or hepatic disease	Approved via the 505(b)(2) pathway, Inzirqo is an oral suspension formulation of hydrochlorothiazide	Non-Formulary
Xpovio (selinexor) 10 mg tablet therapy pack (40 mg once weekly) for multiple myeloma & diffuse large B-cell lymphoma	A new 28-day dosage pack for selinexor (4 x 10 mg tablets), to accommodate a 40 mg dose taken once weekly, has launched.	Formulary
Sevenfact (recombinant coagulation factor VIIa-jncw) 2 mg IV vial for hemophilia A or B with inhibitors	A new 2 mg strength vial of recombinant coagulation factor VIIa recently launched, previously available as 1 mg and 5 mg vials.	Formulary
Ivermectin 6 mg tablet for parasitic infections	A new 6 mg ivermectin tablet was relaunched as it was discontinued in 2009. The relaunched 6 mg tablet has a unit WAC of \$10.35.	Non-Formulary
Combogesic (ibuprofen-acetaminophen) 97.5-325 mg tablet for pain	A new FDA-approved, prescription only, 97.5 mg/325 mg strength of ibuprofen with acetaminophen recently launched.	Non-Formulary
Revuforj (revumenib) 25 mg tablet for relapsed or refractory leukemia with a lysine methyltransferase 2A gene translocation	New 25mg strength launched alongside 110mg and 160mg	Non-Formulary
Tremfya (guselkumab) 20 mg/2 mL autoinjector induction pack for moderately to severely active Crohn's disease	CD pack launched with the new FDA approval for moderate to severe CD	Non-Formulary

June 2025 Pharmacy & Therapeutics Committee Decisions

Ctexli (chenodiol) 250 mg tablets for cerebrotendinous xanthomatosis & Chenodal (chenodiol) 250 mg tablets for gallstones	A new formulation of chenodiol (also known chemically as chenodeoxycholic acid) has launched in Ctexli.	Non-Formulary
Tezruly (terazosin) 1 mg/mL oral solution for benign prostatic hyperplasia and hypertension	Tezruly, an oral terazosin solution, was approved through the 505(b)(2) pathway.	Non-Formulary
Neffy (epinephrine) 1 mg/0.1 mL nasal spray for allergic reactions in patients 15 kg to < 30 kg	New lower dose for patients 15kg to <30kg	Non-Formulary
Sunlenca (lenacapavir) 300 mg tablets for HIV [4 tablet bottle]	New packaging of the same 300mg tablets (previously only available in blister packs)	Formulary
Paxlovid (nirmatrelvir/ritonavir) 6 x 150 mg/5 x 100 mg tablet pack for COVID-19	A new packaging for Paxlovid recently launched to accommodate the dosing in those with severe renal impairment (eGFR < 30 mL/min) including those requiring hemodialysis.	Formulary
Bisoprolol 2.5 mg tablets for hypertension	A single-source branded 2.5 mg strength of bisoprolol launched. >14x the cost of the 5mg tablet	Non-Formulary
Dolobid (diflunisal) 375 mg tablet & 250 mg tablet (previously available) for pain	An additional 375 mg strength of Dolobid (diflunisal) launched. >60x the cost of the generically available 500mg tablet	Non-Formulary
Symbravo (meloxicam-rizatriptan) 20-10 mg tablet for migraine	A new combination of meloxicam and rizatriptan has launched, with a price of \$128 per tablet.	Non-Formulary
Feriva 21/7 Rx multivitamin tablet with iron & Prenate Max Rx prenatal vitamin with iron	Feriva and Prenate Max are prescription-only multivitamins, one of which is a prenatal vitamin.	Non-Formulary
Hemiclor (chlorthalidone) 12.5 mg tablets for hypertension	Hemiclor is a branded 12.5 mg oral chlorthalidone tablet approved through the 505(b)(2) pathway.	Non-Formulary

Additional Items Reviewed

Item	Drugs with New Policies
------	-------------------------

June 2025 Pharmacy & Therapeutics Committee Decisions

New Medical Drug Policies (effective 08/01/25)	<ul style="list-style-type: none">• Emrelis• Envelto• Imaavy
---------------------------------------------------	----------------------------------------------------------------------------------------------